New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

New Findings Suggest Keratin Ingredient Cynatine FLX Activates Joint Defense Enzymes

Lincoln, New Zealand, November 9, 2005 - Recent laboratory research suggests that the new keratin joint ingredient Cynatine FLX activates two important joint antioxidant defense enzymes and stimulates the regeneration of cells.

The findings, released today by Keratec, support the wool-extracted ingredient's innovative four-fold mechanism that:
· helps to prevent joint breakdown and build joint resilience
· has an anti-inflammatory effect
· increases the key antioxidant glutathione and
· provides direct antioxidant protection for cells.

Independent tests on rats demonstrated that orally ingested Cynatine FLX activated two important joint antioxidant defense enzymes, glutathione peroxidase (GSH-PX) and superoxide dismutase (SOD). Cynatine FLX increased the levels of GSH-PX, an important joint antioxidant enzyme that needs glutathione to work and is activated in healthy joints. Cynatine FLX also increased the levels of superoxide dismutase (SOD), another joint antioxidant defense enzyme, which is reduced in damaged joints. This enzyme activation means that Cynatine FLX is not only a strong antioxidant itself, but that it also activates the body's cellular antioxidant machinery to fight damage to joints. The same set of tests indicated that Cynatine supports the body's natural antioxidant processes, shown by reductions in malondialdehde (MDA), a proven biological marker of oxidative stress. In a separate trial, laboratory testing with human and bovine cells demonstrated that Cynatine FLX stimulated cell growth up to 50 percent faster than control samples.

Potential Implications for Joint Health

Taken together, the data supports the case for the four-fold action of Cynatine FLX in helping damaged joints, which frequently suffer from a four-pronged attack. First, shock-absorbing cartilage and other polymers break down and the joint cells lose their ability to make new polymers. Free radicals generated by inflammation cause further damage. Third, the cells of the joint, which normally produce anti-inflammatory molecules like taurine, lose this ability to fight free radicals and finally, glutathione, the body's master antioxidant for fighting free radicals, decreases. Fighting any one of these individual attacks (for example, using glucosamine to build new joint polymers or using antioxidants to fight free radicals) is proven to help joints recover.

Keratec CEO Bruce Foulds said the promising early results lend support to Cynatine FLX's innovative four-fold joint mechanism that addresses a range of joint processes with multiple actions, compared with single-action ingredients on the market.

"We have an ambitious research program in place. We are very excited at the potential of this highly-differentiated product in a market that is becoming increasingly commoditized. We will continue to research and evaluate the efficacy of this ingredient," he said. Keratec and its research partners are further investigating the role of Cynatine FLX in building joint cartilage and supporting the anti-inflammatory response. Full clinical trials are being developed.

About Keratin and Cynatine FLX

Derived from pure New Zealand wool, Cynatine FLX is the world's first intact digestible keratin extract. Keratin, nature's richest protein sulfur source, is the polymer-forming protein of which wool, hair and skin are made. Keratin has the potential to improve parts of the body that require polymers to work, such as joints, which use polymers to absorb shock and keep the joint together.

Traditional keratin-extraction processes dissolve and inactivate the protein's constituent amino acids. Keratec's patent-pending extraction process makes it possible for the first time to leave the natural amino acid structure of keratin intact and therefore fully potent. These pure keratin amino acids are potentially available to the body to support its own joint maintenance and resilience processes.
Cynatine FLX is non-allergenic and, unlike other keratins that need to be dissolved before they can be digested, requires no undesirable stabilizers such as sulphate or hydrochloric acid.

About the Researchers

Cynatine FLX is the culmination of more than 40 years of research into wool properties, keratin ultra-structure and protein chemistry by Keratec and its research partners, which include Canesis Network, the Wellington School of Medicine at the University of Otago (New Zealand), AgResearch New Zealand and YiLing Pharmaceuticals, a large company in the emerging Chinese pharmaceutical industry.

About Keratec (

Keratec is a New Zealand-based biotechnology company producing new materials from natural sources using patent-pending technologies. Its core technologies involve the extraction and purification of intact fractions of natural keratin proteins and lipids from wool sources.

Keratec is a subsidiary of Wool Equities Limited, registered on the New Zealand Stock Exchange under the code NZX: WEL.
For more information, call +64 3 325 6687, email [email protected] or visit the company's web site at

- ends-

For further information, in the U.S. please contact:
Kay Paumier
Communications Plus
[email protected]

Outside the U.S., please contact:
Christine Moore
Flourish Communication Limited
[email protected]

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.